Anmelden Kostenlos registrieren

Starpharma Schwankungsanfälligkeit

Was ist das Schwankungsanfälligkeit von Starpharma?

Schwankungsanfälligkeit von Starpharma Holdings Limited ist 4.21%

Was ist die Definition von Schwankungsanfälligkeit?

Die Schwankungsanfälligkeit oder Prozent des durchschnittlichen wahren Bereichs (ATRP 14) ist die ATR, ausgedrückt als Prozentsatz des Schlusskurses.

Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.

The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.

Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets

Schwankungsanfälligkeit von Unternehmen in Health Care Sektor auf ASX im Vergleich zu Starpharma

Was macht Starpharma?

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Unternehmen mit schwankungsanfälligkeit ähnlich Starpharma